Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Leukemia Research
|
August 1, 2018
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation
Sebastian Sommer, Marjan Cruijsen, Rainer Claus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Blood Advances
|
August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
Annals of Hematology
|
July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
The Lancet. Oncology
|
February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trněný, Thierry Lamy, Jan Walewski, et al.
Bone Marrow Transplantation
|
January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland
Linda Simon, Vladan Vucinic, Kai Rejeski, et al.
Nature Cancer
|
December 21, 2022
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer, Christine Greil, Paul R Wratil, et al.
Blood
|
March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
Wolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Leukemia Research
|
August 1, 2018
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation
Sebastian Sommer, Marjan Cruijsen, Rainer Claus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Blood Advances
|
August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
Annals of Hematology
|
July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
The Lancet. Oncology
|
February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trněný, Thierry Lamy, Jan Walewski, et al.
Bone Marrow Transplantation
|
January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland
Linda Simon, Vladan Vucinic, Kai Rejeski, et al.
Nature Cancer
|
December 21, 2022
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer, Christine Greil, Paul R Wratil, et al.
Blood
|
March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
Wolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Page
of 8